News
-
-
PRESS RELEASE
Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism
Pentixapharm, a subsidiary of Eckert & Ziegler SE, receives FDA feedback to start Phase III trial with radiopharmaceutical diagnostic Ga68-PentixaFor for Primary Aldosteronism -
-
-
-
-
-
PRESS RELEASE
Eckert & Ziegler receives “Best Managed Companies Award”
Eckert & Ziegler SE has been awarded the 'Best Managed Companies Award' by Deloitte Private, UBS, Frankfurter Allgemeine Zeitung, and the Federation of German Industries for outstanding management in strategy, productivity, innovation, culture, and finance -
-
PRESS RELEASE
Eckert & Ziegler with significant increase in sales (+17%) and adjusted EBIT (+41%) in Q1. Forecast 2024 confirmed.
Eckert & Ziegler SE reports strong Q1 results with 17% sales increase and 41% rise in adjusted EBIT. Forecast for 2024 confirmed. Read more: https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz124e.pdf